You are here

  • Home
  • Archive
  • Volume 67, Issue 1
  • Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

Article info

Article menu

Download PDFPDF

Inflammatory bowel disease
Original article
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC
Free

Authors

  • Ingrid Arijs Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium Jessa Hospital, Hasselt, Belgium PubMed articlesGoogle scholar articles
  • Gert De Hertogh Department of Imaging & Pathology, Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Bart Lemmens Department of Imaging & Pathology, Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Leentje Van Lommel Gene Expression Unit, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Magali de Bruyn Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Wiebe Vanhove Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Isabelle Cleynen Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Department of Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Kathleen Machiels Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Marc Ferrante Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Department of Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Frans Schuit Gene Expression Unit, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Gert Van Assche Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Paul Rutgeerts Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Severine Vermeire Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Severine Vermeire, TARGID, KU Leuven, Herestraat 49, O&N1, mailbox 701, Leuven B-3000, Belgium; severine.vermeire{at}uzleuven.be
View Full Text

Citation

Arijs I, De Hertogh G, Lemmens B, et al
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC
Gut 2018;67:43-52.

Publication history

  • Received May 20, 2016
  • Revised September 12, 2016
  • Accepted September 20, 2016
  • First published October 7, 2016.
Online issue publication 
March 26, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/